Loading…
Save Our Medical Devices Act of 2011
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (17)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2012 · fourth_quarter · Health Issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions).H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for Transcutaneous Electronic Stimulation for chronic lower back pain. Issue relating to MDUFA fees and sequestration.
Client expense: $490,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · first_quarter · Health Issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions).H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally)
2012 · fourth_quarter · Taxation/Internal Revenue Code
Clean Energy Advanced Manufacturing Tax Credit (48c) Renewable energy production tax credit extensions R&D Tax Credit Extension Medical Device Excise Tax S. 262, Repeal of Medical Device Tax H.R. 488, Save Our Medical Devices Act of 2011 H.R. 436, Protect Medical Innovation Act of 2011 S. 17, Medical Device Access and Innovation Protection Act
Client expense: $1,275,023 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Export-Import Bank of the United States (EXIM Bank), Federal Energy Regulatory Commission (FERC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Security Council (NSC), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488, H.R.734 and H.R.8, the American Taxpayer Relief Act of 2012.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
Issues relating to the repeal of the medical device excise tax including S.17, S.262, H.R.436, H.R.488, H.R.734 and H.R.8, The American Taxpayer Relief Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
| Democratic |
| PA |
| Joseph R. Pitts | Republican | PA |
| Lou Barletta | Republican | PA |
| Michael G. Fitzpatrick | Republican | PA |
| Mike Kelly | Republican | PA |
| Patrick Meehan | Republican | PA |
| Ron Paul | Republican | TX |
| Tim Holden | Democratic | PA |
| Tim Murphy | Republican | PA |
| Todd Russell Platts | Republican | PA |
| Tom Marino | Republican | PA |
| W. Todd Akin | Republican | MO |
Client expense: $720,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734; tax policies as they relate to the competitiveness of the medical device industry, and H.R.8, The American Taxpayer Relief Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488, H.R.734 and H.R.8, the American Taxpayer Relief Act of 2012.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
Issues relating to the repeal of the medical device excise tax including S.17, S.262, H.R.436, H.R.488, H.R.734 and H.R.8, The American Taxpayer Relief Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
Client expense: $880,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · fourth_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734; tax policies as they relate to the competitiveness of the medical device industry, and H.R.8, The American Taxpayer Relief Act of 2012.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
S. 17, S. 262, HR 436, HR 488, HR 734 bills related to the Medical Device Excise Tax [Elizabeth Kegler, Elizabeth Sharp, JC Scott, Duane Wright]
Client expense: $453,093 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
H.R. 436 (H.R.488, H.R.734, S.17, S.262) - Protect Medical Innovation Act of 2011, device tax repeal H.R. 8 - American Taxpayer Relief Act of 2012, device tax
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
S.17, the Medical Device and Innovation Protection Act - a bill to repeal the medical device tax S. 262, A bill to repeal the excise tax on medical device manufacturers H.R. 436, the Protect Medical Innovation Act - a bill to repeal the medical device tax H.R. 734, To amend the Internal Revenue Code of 1986 to repeal the medical device tax; H.R.488, Save Our Medical Devices Act of 2011 - a bill to repeal the medical device tax H.R. 942, American Research and Competitiveness Act of 2011 - a bill to extend the research credit through 2012 S.239, the Innovate America Act, a bill to support innovation through tax credits such as research and development S. 1866, the Agree Act which calls for an increase in the rate of hte alternative simplified research tax credit and makes such credit permanent Corporate tax reform - specifically the treatment of international earnings including the Chairman's International Tax Reform
Client expense: $370,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation Device tax repeal bills (S.17/H.R. 436, S. 262/H.R. 734, H.R. 488)
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · fourth_quarter · Health Issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions). H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for Transcutaneous Electronic Stimulation for chronic lower back pain. Issue relating to MDUFA fees and sequestration.
Client expense: $470,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · fourth_quarter · Taxation/Internal Revenue Code
Legislation to repeal the Medical Device Excise Tax, S. 17, S. 262, H.R. 436, H.R. 734, H.R. 488
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
See page three Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 6446 Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
See page 7 Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 6446 Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
See page five Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S.1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 6446 Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
2012 · fourth_quarter · Taxation/Internal Revenue Code
PL 111-152, Sec. 1405 - Medical Device Excise Tax S 262 - "A bill to repeal the excise tax on medical device manufacturers" Device Repeal Bills: S 19, HR 436, HR 488, HR 734
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
2012 · fourth_quarter · Health Issues
Issues relating to oral-health and dental practice in the following bills: H.R. 2/S. 192, Repealing the Job-Killing Health Care Law Act; H.R. 5/S. 218, S. 1099, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 38, A bill to rescind funds appropriated to the Health Insurance Reform Implementation Fund under the Health Care and Education Reconciliation Act of 2010; HR105, Empowering Patients First Act; HR157, Health Care Safety Net Enhancement Act of 2011; HR165, Informed Choice Act; H.R. 969, the Medical Practice Freedom Act of 2011; H.R. 314, Medical Liability Procedural Reform Act of 2011; H.R. 570, Dental Emergency Responder Act; H.R. 1578/S. 1765, Violence Against Women Health Initiative Act of 2011; H.R. 2119, Ryan Creedon Act of 2011; H.R. 2405/S. 1855, Pandemic and All Hazards Preparedness Act of 2011; H.R. 3586, Good Samaritan Health Professionals Act of 2011; S. 197, Medical Care Access Protection (MCAP) Act of 2011; S. 312/H.R. 605, Patients Freedom to Choose Act; S. 966, Bone Health Promotion and Research Act of 2011; S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act; S. 1878/H.R. 4091, Coordination of Pro Bono Medically Recommended Dental Care Act; S. 1925, Violence Against Women Reauthorization Act of 2011; H.R. 3765, Temporary Payroll Tax Cut Continuation Act of 2011; H.R. 3839, Drug Shortage Prevention Act of 2012; S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act; S. 3187 [H.R. 5651] - Prescription Drug User Fee Act. H.R. 5909 - Comprehensive Dental Reform Act of 2012 H.R. 5979 - Medicaid Accountability and Care Act of 2012 S. 3272 - Comprehensive Dental Reform Act of 2012 Community water fluoridation Medicaid and CHIP Payment and Access Commission: -Center for Consumer Information and Insurance Oversight; -Center for Medicaid, CHIP and Survey and Certification; Implementation of P.L. 111-148; 111-152, Patient Protection and Affordable Care Act; Oral-health issues within Secretary's Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020, Healthy People 2020; Comments on planning and establishment of state level exchanges; Office of the Assistant Secretary for Preparedness and Response, National Health Security Strategy (biennial implementation plan), National Disaster Medical System (disaster medical assistance team) regarding issues related to utlization of dental professionals in the event of a disaster; Office of Global Health (United Nations high-level meeting on non-communicable diseases); Division of Oral Health Reorganization; CMS Limited English Proficiency Guidelines; Advisory Committee on Training in Primary Care Medicine and Dentistry Nominations, Ninth Report to Congress; National Advisory Dental and Craniofacial Research Council Nominations; Center for Substance Abuse Treatment, National Recovery Month; United Nations Summit on Non-Communicable Diseases; National Drug Control Strategy / Prescription Drug Abuse Prevention Plan; DEA National Prescription Drug Take Back Campaign; FDA Center for Drug Evaluation and Research regarding dry mouth labeling; Medical/Dental Coding Issues; Comparative Effectiveness regarding Dental Quality Alliance; Health Information Technology (HIT) Regulations; Health care issues before the Joint Select Committee on Deficit Reduction. United Nations General Assembly's High-level Meeting on Non-communicable Diseases CMS proposed rule on reporting and returning Medicare overpayments Food and Drug Administration Sedation Product Guidance Centers for Disease Control and Prevention recommendations for identification of persons with Hepatitis C (HCV) chronic infection H.R. 5711 - Access to Substance Abuse Treatment Act of 2012 Department of Health and Human Services media campaign to educate the public about the dangers of tobacco use SAMHSA National Recovery Month Food and Drug Administration clinical development and use of sedation products Surgeon General report on sugar-sweetened beverages S. 3562, Older Americans Act Amendments of 2012 HR 436, Protect Medical Innovation Act of 2011 (Medical Device Tax) HR 488, Save Our Medical Devices Act of 2011 (Medical Device Tax) S 17, Medical Device Access and Innovation Protection Act (Medical Device Tax) S 262, To repeal the excise tax on medical device manufacturers (Medical Device Tax)
Client expense: $620,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Other), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Natl Institutes of Health (NIH), Navy, Dept of, Occupational Safety & Health Administration (OSHA), Office of Natl Drug Control Policy (NDCP), SENATE, State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
2012 · fourth_quarter · Health Issues
Changes to Medicare regarding durable medical equipment benefits. H.R. 436 Protect Medical Innovation Act of 2011; H.R. 488 Save our Medical Devices Act of 2011; H.R. 734 - to amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes; S. 17 Medical Device Access and Innovation Protection Act and S. 262 - A bill to repeal the excise tax on medical device manufacturers
Client expense: $220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
S. 17, S. 262, HR 436, HR 488, HR 734 bills related to the Medical Device Excise Tax [Elizabeth Kegler, Elizabeth Sharp, JC Scott, Duane Wright] Issues related to tax reform [JC Scott]
Client expense: $366,862 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
S. 17, S. 262, HR 436, HR 488, HR 734 bills related to the Medical Device Excise Tax [Elizabeth Kegler, Elizabeth Sharp, JC Scott, Duane Wright] H.R. 6353 Manufacturing American Innovation Act of 2012 [Elizabeth Sharp]
Client expense: $267,490 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
Issues relating to the repeal of the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
Client expense: $1,420,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · third_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R. 734; tax policies as they relate to the competitiveness of the medical device industry.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation Device tax repeal bills (S.17/H.R. 436, S. 262/H.R. 734, H.R. 488)
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
See page five Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 HR 6446, Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
See page three Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 HR 6446, Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
See page 7 Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 HR 6446, Improving Diagnostic Innovations Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), SENATE
2012 · third_quarter · Health Issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions). H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for Transcutaneous Electronic Stimulation for chronic lower back pain.
Client expense: $460,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · first_quarter · Health Issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions). H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally)
Client expense: $700,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
S. 17, the Medical Device and Innovation Protection Act - a bill to repeal the medical device tax S. 262, A bill to repeal the excise tax on medical device manufacturers H.R. 436, the Protect Medical Innovation Act - a bill to repeal the medical device tax H.R. 734, To amend the Internal Revenue Code of 1986 to repeal the medical device tax; H.R. 488, Save Our Medical Devices Act of 2011 - a bill to repeal the medical device tax H.R. 942, American Research and Competitiveness Act of 2011 - a bill to extend the research credit through 2012 S. 239, the Innovate America Act, a bill to support innovation through tax credits such as research and development S. 1866, the Agree Act which calls for an increase in the rate of the alternative simplified research tax credit and makes such credit permanent Corporate tax reform - specifically the treatment of international earnings including the Chairman's International Tax Reform discussion draft
Client expense: $360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
Legislation to repeal the Medical Device Excise Tax, S. 17, S. 262, H.R. 436, H.R. 734, H.R. 488
Client expense: $45,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Taxation/Internal Revenue Code
H.R. 436 (H.R.488, H.R.734, S.17, S.262) - Protect Medical Innovation Act of 2011, device tax repeal
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · third_quarter · Health Issues
Changes to Medicare regarding durable medical equipment benefits. H.R. 436 Protect Medical Innovation Act of 2011; H.R. 488 Save our Medical Devices Act of 2011; H.R. 734 - to amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes; S. 17 Medical Device Access and Innovation Protection Act and S. 262 - A bill to repeal the excise tax on medical device manufacturers
Client expense: $320,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), SENATE
Please see next page Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Please see attached page Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Please see next page Lobbying Issues: Molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues H.R. 436/ S. 17 Protect Medical Innovation Act of 2011 H.R. 488 Save Our Medical Devices Act of 2011 H.R. 755 Investing in Our Future Act of 2011 H.R. 965/ S. 1211 Preservation of Antibiotics for Medical Treatment Act of 2011 H.R. 2182 / S. 1732 Generating Antibiotic Incentives Now (GAIN) Act H.R. 3203 Novel Device Regulatory Relief Act of 2011 H.R. 3204 Guidance Accountability and Transparency Act of 2011 H.R. 3205 FDA Renewing Efficiency from Outside Review Management Act of 2011 H.R. 3206 Cultivating Scientific Experts to Foster Innovation Act of 2011 H.R. 3207 Modernizing Laboratory Test Standards for Patients Act of 2011 H.R. 3208 Patients Come First Act of 2011 H.R. 3209 Premarket Predictability Act of 2011 H.R. 3211 Humanitarian Device Reform Act of 2011 H.R. 3214 / S. 1972 Food and Drug Administration Mission Reform Act of 2011 H.R. 3230 Keeping America Competitive through Harmonization Act of 2011 H.R. 3497 Modernizing Our Drug & Diagnostics Evaluation and Regulation Network (MODDERN) Cures Act of 2011 H.R. 5651, the Food and Drug Administration Reform Act of 2012 S. 660 Preserving Access to Targeted Individualized and Effective New Treatments and Services (PATIENTS) Act of 2011 S. 1700 The Medical Device Regulatory Improvement Act S. 1865 The Patient Access to Medical Innovation Act S. 1943 Novel Device Regulatory Relief Act of 2011 S. 1995 Medical Device Patient Safety Act S. 3187, the Food and Drug Administration Safety and Innovation Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
S. 17, S. 262, HR 436, HR 488, HR 734 bills related to the Medical Device Excise Tax [Elizabeth Kegler, Elizabeth Sharp, JC Scott, Duane Wright] Issues related to tax reform [JC Scott]
Client expense: $559,267 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
- Issues regarding tax reform. - HR 605, "The Patients' Freedom to Choose Act", regarding all provisions. - HR 436, "Protect Medical Innovation Act of 2011", regarding all provisions. - HR 488, "Save Our Medical Devices Act of 2011", regarding all provisions. - HR 734, "To amend the Internal Revenue Code of 1986 to repeal the medical device tax, and for other purposes", regarding all provisions. - S 17, "Medical Device Access and Innovation Protection Act", regarding all provisions. - S 262, "A bill to repeal the excise tax on medical device manufacturers", regarding all provisions. - HR 942, "American Research and Competitiveness Act of 2011", regarding all provisions - Issues related to tax legislation. - Issues related to the President's proposed "Job Bill" (2011) - S 1368/ HR 2529, "Restoring Access to Medication Act", regarding all provisions. - S 1584, "Drug Safety and Accountability Act of 2011", regarding all provisions. - HR 2245, "Preserving Access to Life-Saving Medication Act", regarding all provisions. - Issues related to Ways and Means tax reform discussion draft. - HR 2735, "To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations", regarding all provisions. - S 1577, "Greater Research Opportunities With Tax Help Act", regarding all provisions. - PL 112-96, "Middle Class Tax Relief and Job Creation Act of 2012", provisions regarding Medicare clinical laboratory services. - HR 1864, "Mobile Workforce State Income Tax Simplification Act of 2011", regarding all provisions. - S 2091, "United States Job Creation and International Tax Reform Act of 2012", regarding all provisions.
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · second_quarter · Taxation/Internal Revenue Code
Legislation to repeal the Medical Device Excise Tax: S. 17, S. 262, H.R. 436, H.R. 734, H.R. 488
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
Issues relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734; tax policies as they relate to the competitiveness of the medical device industry.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
Tax proposals relating to the medical device excise tax including S.17, S.262, H.R.436, H.R.488 and H.R.734.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
Clean Energy Advanced Manufacturing Tax Credit (48c) Renewable energy production tax credit extensions R&D Tax Credit Extension Medical Device Excise Tax S. 262, Repeal of Medical Device Tax H.R. 488, Save Our Medical Devices Act of 2011 H.R. 436, Protect Medical Innovation Act of 2011 S. 17, Medical Device Access and Innovation Protection Act
Client expense: $1,417,891 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Export-Import Bank of the United States (EXIM Bank), Federal Energy Regulatory Commission (FERC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Security Council (NSC), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2012 · second_quarter · Taxation/Internal Revenue Code
PL 111-148 - The Patient Protection and Affordable Care Act, PL 111-152 - The Reconciliation Act of 2010, implementation Device tax repeal bills (S.17/H.R. 436, S. 262/H.R. 734, H.R. 488)
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2012 · second_quarter · Taxation/Internal Revenue Code
H.R. 436 (H.R.488, H.R.734, S.17, S.262) - Protect Medical Innovation Act of 2011, device tax repeal
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE